Loading…
Sheel Biotech (SHEEL)₹61.00+3.13%Diversified Commercial Services
In the Sep 2025 quarter (standalone), Sheel Biotech reported sales of ₹21.92 Cr, up 99.8% from Sep 2024, and net profit of ₹0 Cr. For the year to Mar 2026, sales were ₹110 Cr and net profit ₹12.03 Cr.
Company filings, standalone accounts; latest reported quarter Sep 2025
| Sep 2024 | Sep 2025 | |
|---|---|---|
| Sales | 10.97 | 21.92 |
| Expenses | 13.96 | 19.93 |
| Operating Profit | −1.99 | 1.99 |
| OPM % | −21.9% | 8.1% |
| Other Income | 0.00 | 0.00 |
| Interest | 0.99 | 0.99 |
| Depreciation | 0.00 | 1.01 |
| Profit before tax | −4.01 | 0.00 |
| Tax % | 3.0% | 24.1% |
| Net Profit | −4.01 | 0.00 |
| EPS (Rs) | −2.54 | 0.14 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 62.82 | 83.76 | 88.77 | 103 | 110 | 110 |
| Expenses | 55.78 | 77.79 | 79.75 | 88.77 | 94.65 | 93.70 |
| Operating Profit | 6.99 | 5.99 | 8.99 | 13.98 | 14.99 | 15.99 |
| OPM % | 10.0% | 8.0% | 10.0% | 14.1% | 14.1% | 15.1% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 |
| Interest | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 1.99 |
| Depreciation | 0.99 | 1.01 | 0.99 | 0.99 | 0.99 | 0.99 |
| Profit before tax | 5.01 | 5.01 | 6.01 | 12.02 | 13.01 | 14.02 |
| Tax % | 0.0% | 2.0% | 20.1% | 15.1% | 17.1% | 16.1% |
| Exceptional items | 0.09 | 0.02 | 0.00 | 0.00 | 0.24 | 0.00 |
| Net Profit | 5.01 | 5.01 | 5.01 | 10.02 | 11.02 | 12.03 |
| EPS (Rs) | 11.59 | 10.90 | 12.27 | 25.31 | 7.13 | 5.79 |
| Dividend payout % | 0.0% | 28.0% | 25.0% | 12.0% | 14.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 4.00 | 4.00 | 15.00 |
| Reserves | 52.94 | 55.98 | 58.92 | 68.94 | 68.96 |
| Borrowings | 21.00 | 24.02 | 19.00 | 24.00 | 17.01 |
| Other Liabilities | 3.98 | 9.95 | 10.95 | 9.96 | 11.95 |
| Total Liabilities | 81.92 | 92.95 | 93.87 | 106 | 113 |
| Fixed Assets | 7.99 | 7.99 | 7.99 | 7.01 | 7.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 |
| Other Assets | 74.93 | 83.95 | 84.87 | 97.88 | 105 |
| Inventories | 6.01 | 12.02 | 19.02 | 33.03 | 39.07 |
| Trade receivables | 60.97 | 65.05 | 56.04 | 58.02 | 54.99 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| Total Assets | 81.92 | 92.95 | 93.87 | 106 | 113 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 2.01 | 9.01 | −1.01 | 9.01 | −18.02 |
| Cash from investing activity | −2.01 | −2.01 | 0.00 | −2.01 | −7.01 |
| Cash from financing activity | 0.00 | −7.01 | 2.01 | −7.01 | 26.01 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 |
| Capex | 1.22 | 1.16 | 0.30 | 1.25 | 6.68 |
| Free cash flow | 0.99 | 7.98 | −0.99 | 7.98 | −23.95 |
| CFO / OP % | 37.1% | 105.0% | 3.0% | 75.1% | −93.9% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor days | 353 | 281 | 231 | 205 | 183 |
| Inventory days | 54 | 119 | 176 | 262 | 271 |
| Days payable | 29 | 84 | 74 | 36 | 28 |
| Cash conversion cycle | 377 | 315 | 332 | 430 | 426 |
| Working capital days | 347 | 273 | 254 | 255 | 252 |
| ROCE % | — | 7.1% | 10.1% | 15.1% | 14.1% |
For the Sep 2025 quarter, Sheel Biotech reported sales of ₹21.92 Cr, up 99.8% year on year and net profit of ₹0 Cr. The operating margin was 8.1%.
Sheel Biotech's sales for the year to Mar 2026 were ₹110 Cr.
Net profit for the year to Mar 2026 was ₹12.03 Cr. Earnings per share over the same trailing period were ₹5.79.
Sheel Biotech reported borrowings of ₹17.01 Cr at Mar 2025, against cash and equivalents of ₹0 Cr.
Cash from operations was −₹18.02 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹23.95 Cr.